RecruitingFrontotemporal Lobar DegenerationAlzheimer DiseaseCognitively Normal
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
Sponsor: University of Pennsylvania
You may qualify if…
- ✓ 1\. Group 1: cognitively and neurologically normal subjects (CN, n=25)
- ✓ 1. Male or female ≥ 18 years of age currently enrolled in UNICORN (IRB #842873)
- ✓ 2. Cognitively and neurologically normal according to one of the following criteria:
- ✓ i. Mini-Mental Status Exam (MMSE; Folstein et al., 1975) score \> 27, OR ii. Montreal Cognitive Assessment (MoCA; Carson et al., 2017; Nasreddine et al., 2005) score \> 25, OR iii. Global Clinical Dementia Rating of 0, OR iv. Evaluation by a trained clinician
- ✓ 3. Not clinically depressed, according to one of the following criteria:
- ✓ i. Geriatric Depression scale ≤ 6 (assessed ≤ 6 months prior to study enrollment), OR ii. Evaluation by a trained clinician
- ✓ 4. No history of early-onset neurodegenerative disease in biological siblings or parents, based on the investigators' assessment of the participant's self-reported history.
- ✓ 2\. Group 2: non-amnestic Alzheimer's disease (naAD, n=15)
You may not qualify if…
- ✕ 1. The participant has any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the participant's safety or successful participation in the study.
- ✕ 2. The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI scan within \< 6 months prior to enrollment that is likely to interfere with analysis of the PET scan.
- ✕ 3. The participant is unable to tolerate or have a contraindication to imaging procedures in the opinion of an investigator.
- ✕ 4. Females who are pregnant or breast feeding at the time of the baseline PET/CT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET/CT.
- ✕ 5. The participant has a history of significant past or ongoing alcohol abuse or substance abuse, or dependence based on medical record review or self-reported (may be excluded at the discretion of the investigator.)
- ✕ 6. The participant is enrolled in a clinical trial for a disease-modifying treatment that targets the molecular pathology underlying their neurodegenerative disease.
Where it's recruiting
Pennsylvania
Philadelphia
Source: ClinicalTrials.gov · NCT05456503 · last updated 2025-11-04